Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BSX Stock Forecast 2025-2026
$100.02
Current Price
$148.27B
Market Cap
Buy 32
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to BSX Price Targets
+40.0%
To High Target of $140.00
+29.5%
To Median Target of $129.50
-1.0%
To Low Target of $99.00
BSX Price Momentum
-0.7%
1 Week Change
+2.8%
1 Month Change
+13.3%
1 Year Change
+12.0%
Year-to-Date Change
-8.7%
From 52W High of $109.50
+16.3%
From 52W Low of $85.98
📊 TOP ANALYST CALLS
Did BSX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Boston Scientific is one of their latest high-conviction picks.
Latest BSX Stock Price Targets & Analyst Predictions
Based on our analysis of 32 Wall Street analysts, BSX has a bullish consensus with a median price target of $129.50 (ranging from $99.00 to $140.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $100.02, the median forecast implies a 29.5% upside. This outlook is supported by 32 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Danielle Antalffy at UBS, projecting a 40.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BSX Analyst Ratings
32
Buy
2
Hold
0
Sell
BSX Price Target Range
Low
$99.00
Average
$129.50
High
$140.00
Current: $100.02
Latest BSX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BSX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 23, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $130.00 |
| Oct 23, 2025 | UBS | Danielle Antalffy | Buy | Maintains | $140.00 |
| Oct 23, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $125.00 |
| Oct 23, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $132.00 |
| Oct 23, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $130.00 |
| Oct 22, 2025 | BTIG | Marie Thibault | Buy | Reiterates | $132.00 |
| Oct 17, 2025 | Needham | Mike Matson | Buy | Reiterates | $121.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $110.00 |
| Oct 2, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $136.00 |
| Oct 1, 2025 | BTIG | Marie Thibault | Buy | Maintains | $132.00 |
| Oct 1, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $132.00 |
| Oct 1, 2025 | Leerink Partners | Mike Kratky | Outperform | Maintains | $128.00 |
| Oct 1, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $129.00 |
| Oct 1, 2025 | Needham | Mike Matson | Buy | Reiterates | $121.00 |
| Oct 1, 2025 | Baird | David Rescott | Outperform | Maintains | $128.00 |
| Sep 29, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $125.00 |
| Sep 23, 2025 | BTIG | Marie Thibault | Buy | Reiterates | $127.00 |
| Sep 19, 2025 | Needham | Mike Matson | Buy | Reiterates | $121.00 |
| Sep 11, 2025 | Needham | Mike Matson | Buy | Reiterates | $121.00 |
| Sep 8, 2025 | Oppenheimer | Steven Lichtman | Outperform | Upgrade | $125.00 |
Boston Scientific Corporation (BSX) Competitors
The following stocks are similar to Boston Scientific based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BSX
Boston Scientific
mkt cap
148.27B
Boston Scientific Corporation (BSX) Financial Data
Boston Scientific Corporation has a market capitalization of $148.27B with a P/E ratio of 53.5x. The company generates $19.35B in trailing twelve-month revenue with a 14.4% profit margin.
Revenue growth is +20.3% quarter-over-quarter, while maintaining an operating margin of +20.7% and return on equity of +12.5%.
Valuation Metrics
Market Cap
$148.27B
Enterprise Value
$157.84B
P/E Ratio
53.5x
PEG Ratio
0.4x
Price/Sales
7.7x
Growth & Margins
Revenue Growth (YoY)
+20.3%
Gross Margin
+67.7%
Operating Margin
+20.7%
Net Margin
+14.4%
EPS Growth
+61.0%
Financial Health
Cash/Price Ratio
+0.9%
Current Ratio
1.5x
Debt/Equity
51.0x
ROE
+12.5%
ROA
+5.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Boston Scientific Corporation (BSX) Business Model
About Boston Scientific Corporation
What They Do
Develops innovative medical devices for healthcare.
Business Model
Boston Scientific designs, manufactures, and markets medical devices for interventional specialties, generating revenue primarily through sales to healthcare providers and institutions. By focusing on minimally invasive treatments, the company enhances patient care while reducing healthcare costs.
Additional Information
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific is influential in the healthcare sector, driving advancements in medical technology through ongoing research and development.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
53,000
CEO
Mr. Michael F. Mahoney
Country
United States
IPO Year
1992
Website
www.bostonscientific.comBoston Scientific Corporation (BSX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
AMN Stock Gains Following Q3 Earnings & Revenue Beat, Margins Down
AMN Healthcare beats third-quarter 2025 earnings and revenue estimates despite lower margins and year-over-year declines across key segments.
Nov 07, 2025
By Zacks Equity Research
Analyst Blog
Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y
DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.
Nov 07, 2025
By Zacks Equity Research
Analyst Blog
QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand
QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.
Nov 06, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
BSX reported a 63% increase in Q3 EP sales, driven by momentum from FARAPULSE, FDA label expansion, and growing global adoption.
Why It Matters
BSX's Q3 EP sales surge indicates strong product demand and market expansion, signaling potential revenue growth and increased investor confidence in the company's future performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Bet on 5 Top-Ranked Stocks With Rising P/E
4 days ago
Quick Summary
Five stocks with increasing P/E ratios are The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix, and Boston Scientific, suggesting potential investment opportunities.
Why It Matters
Rising P/E ratios can indicate growth expectations, signaling potential investment opportunities in these specific stocks, which may outperform the market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The firm initiated new positions in Spotify, L3Harris Technologies, and Insmed, while increasing stakes in 3i Group, West Pharmaceutical, and Amazon. They exited investments in Atlassian, Adidas, and Vertex Pharmaceuticals.
Why It Matters
Changes in investment positions signal confidence or reassessment of growth potential in these companies, impacting stock prices and investor strategies.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences, as announced on November 3, 2025.
Why It Matters
Boston Scientific's participation in investor conferences signals potential insights on company performance and strategy, impacting investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intuitive Surgical and Boston Scientific reported strong Q3 results, but their differing growth strategies present unique investment considerations.
Why It Matters
The differing growth strategies of Intuitive Surgical and Boston Scientific signal varied risk and return profiles, influencing investment decisions and portfolio diversification.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Global aging is increasing healthcare demand, benefiting companies like AbbVie, Amgen, Boston Scientific, and Edwards.
Why It Matters
Global aging increases healthcare demand, benefiting companies like AbbVie, Amgen, Boston Scientific, and Edwards, which could see growth in revenues and market share.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About BSX Stock
What is Boston Scientific Corporation's (BSX) stock forecast for 2026?
Based on our analysis of 32 Wall Street analysts, Boston Scientific Corporation (BSX) has a median price target of $129.50. The highest price target is $140.00 and the lowest is $99.00.
Is BSX stock a good investment in 2026?
According to current analyst ratings, BSX has 32 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $100.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BSX stock?
Wall Street analysts predict BSX stock could reach $129.50 in the next 12 months. This represents a 29.5% increase from the current price of $100.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Boston Scientific Corporation's business model?
Boston Scientific designs, manufactures, and markets medical devices for interventional specialties, generating revenue primarily through sales to healthcare providers and institutions. By focusing on minimally invasive treatments, the company enhances patient care while reducing healthcare costs.
What is the highest forecasted price for BSX Boston Scientific Corporation?
The highest price target for BSX is $140.00 from Danielle Antalffy at UBS, which represents a 40.0% increase from the current price of $100.02.
What is the lowest forecasted price for BSX Boston Scientific Corporation?
The lowest price target for BSX is $99.00 from at , which represents a -1.0% decrease from the current price of $100.02.
What is the overall BSX consensus from analysts for Boston Scientific Corporation?
The overall analyst consensus for BSX is bullish. Out of 32 Wall Street analysts, 32 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $129.50.
How accurate are BSX stock price projections?
Stock price projections, including those for Boston Scientific Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 10:25 AM UTC